Application of the “immunization islands” model to improve quality, efficiency and safety of a COVID-19 mass vaccination site
Keywords:
Mass immunization centers, COVID-19, vaccination, adverse effectsAbstract
After SARS-CoV-2 vaccines development came at an unprecedented speed, ensuring safe and efficient mass immunization, vaccine delivery became the major public health mandate. Although mass-vaccination sites have been identified as essential to curb COVID-19, their organization and functioning is challenging. In this paper we present the planning, implementation and evaluation of a massive vaccination center in Lombardy - the largest Region in Italy and the most heavily hit by the pandemic. The massive hub of Novegro (Milan), managed by the Gruppo Ospedaliero San Donato, opened in April 2021. The Novegro massimmunization model was developed building a layout based on the available scientific evidence, on comparative analysis with other existing models and on the experience of COVID-19 immunization delivery of Gruppo Ospedaliero San Donato. We propose a “vaccine islands” mass-immunization model, where 4 physicians and 2 nurses operate in each island, with up to 10 islands functioning at the same time, with the capacity of providing up to 6,000 vaccinations per day. During the first week of activity a total of 37,900 doses were administered (2,700/day), most of them with Pfizer vaccine (85.8%) and first doses (70.9%). The productivity was 10.5 vaccines/hour/vaccine station. Quality, efficiency and safety were boosted by ad-hoc personnel training, quality technical infrastructure and the presence of a shock room. Constant process monitoring allowed to identify and promptly tackle process pitfalls, including vaccine refusals (0.36%, below expectations) and post-vaccinations adverse reactions (0.4%). Our innovative “vaccine islands” mass-immunization model might be scaled-up or adapted to other settings. The Authors consider that sharing best practices in immunization delivery is fundamental to achieve population health during health emergencies.
References
1. European Medicines Agency. Treatments and vaccines for COVID-19: European Union; 2021. Available on: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-diseasecovid-19/treatments-vaccines-covid-19 [Last accessed: 2021 May 21].
2. Food and Drug Administration. COVID-19 Vaccines 2021. Available on: https://www.fda.gov/emergencypreparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines [Last accessed 2021 May 21].
3. Odone A, Delmonte D, Scognamiglio T, Signorelli C. COVID-19 deaths in Lombardy, Italy: data in context. Lancet Public Health. 2020; 5(6): e310. doi: 10.1016/S2468-2667(20)30099-2. Epub 2020 Apr 25.
4. Signorelli C, Odone A, Gianfredi V, et al. The spread of COVID-19 in six western metropolitan regions:
a false myth on the excess of mortality in Lombardy and the defense of the city of Milan. Acta Biomed. 2020 May 20; 91(2): 23-30. doi: 10.23750/abm.v91i2.9600.
5. Signorelli C, Odone A, Gianfredi V, et al. COVID-19 mortality rate in nine high-income metropolitan regions. Acta Biomed. 2021 Jul 20; 91(9-S): 7-18. doi: 10.23750/abm.v91i9-S.10134.
6. Paciullo F, Giannandrea D, Gianfredi V, et al. Epidemiology of emergency calls for time-dependent acute illnesses during COVID-19 outbreak in Umbria region (Italy). Ann Ig. 2021 Mar-Apr; 33(2): 198-200. doi: 10.7416/ai.2020.2392. Epub 2020 Dec 3.
7. European Centre for Disease Prevention and Control (ECDC). COVID-19 vaccination and prioritisation strategies in the EU/EEA. Stockholm; 22 December 2020.
8. Goralnick E, Kaufmann C, Gawande AA. Mass-Vaccination Sites - An Essential Innovation to Curb the Covid-19 Pandemic. N Eng J Med. 2021 May 6; 384(18): e67. doi: 10.1056/NEJMp2102535. Epub 2021 Mar 10.
9. Ministero della Salute. Piano Nazionale Prevenzione Vaccinale PNPV 2017-2019. Rome; 2017.
10. Ministero della Salute. Vaccinazione anti-SARS-CoV-2/COVID-19 piano strategico. Elementi di preparazione e di implementazione della strategia vaccinale. Rome; 2021.
11. Signorelli C, Guerra R, Siliquini R, Ricciardi W. Italy’s response to vaccine hesitancy: An innovative and cost effective National Immunization Plan based on scientific evidence. Vaccine. 2017 Jul 24; 35(33): 4057-9. doi: 10.1016/j.vaccine.2017.06.011. Epub 2017 Jun 23.
12. Bonanni P, Chiamenti G, Conforti G, et al. The 2016 Lifetime Immunization Schedule, approved by the Italian scientific societies: A new paradigm to promote vaccination at all ages. Hum Vaccin Immunother. 2017 Nov 2; 13(11): 2531-7. doi: 10.1080/21645515.2017.1366394.
13. Ministero della Salute. Circolare n. 42164. 24th December 2020.
14. Presidenza del Consiglio dei Ministri Commissario Straordinario per l’attuazione e il coordinamento delle misure sanitarie di contenimento e contrasto dell’emergenza epidemiologica COVID-19. Piano Vaccinale anti-COVID-19. Rome; 2021. Available at: https://www.governo.it/sites/governo.it/files/210313_Piano_Vaccinale_marzo_2021_1.pdf
15. Gianfredi V, Pennisi F, Lume A, et al. Challenges and opportunities of mass vaccination centers in COVID-19 times: a rapid systematic review of literature. Vaccines 2021; 9(6): 574. https://doi.org/10.3390/ vaccines9060574
16. Gupta A, Evans GW, Heragu SS. Simulation and optimization modeling for drive-through mass vaccination - A generalized approach. Simul Model Pract Theory. 2013 Sep; 37: 99-106. https://doi.org/10.1016/j. simpat.2013.06.004.
17. Jenlink CH, Kuehnert P, Mazyck D. Influenza vaccinations, fall 2009: model school-located vaccination clinics. J Sch Nurs 2010 Aug; 26(4 Suppl):7s-13s. doi: 10.1177/1059840510368960. Epub 2010 Apr 23.
18. Regione Lombardia. Delibera regionale n XI / 4384: Individuazione dei punti vaccinali in attuazione della dgr. N. Xi/4353 del 24/02/2021 “approvazione del piano regionale vaccini per la prevenzione delle infezioni da SARS-CoV-2”. 2021.
19. Capolongo S, Brambilla A, Girardi A, Signorelli C. An evaluation checklist for massive vaccination centers. Ann Ig. 2021 Sep-Oct; 33(5): 513-7. Epub 2021 Jun 11. doi: 10.7416/ai.2021.2460.
20. Ministero della Salute. Circolare 7 aprile 2021: Vaccino Vaxzevria (precedentemente denominato COVID19 Vaccine AstraZeneca). Aggiornamento raccomandazioni. Rome; 2021.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.